Abstract

The family of Janus kinases (JAK) play an important role in several disease areas, including oncology, immunology/ inflammation and longevity, and have also been identified as potential therapeutic targets for COVID-19. Arctoris deployed its automated drug discovery platform, Ulysses, to generate a comprehensive dataset on 24 small molecules against all four members of the JAK family. In under 100 h, the platform completed an extensive experimental program resulting in a large, structured dataset revealing a diverse set of pharmacologically distinct profiles.